Phase I trial of concurrent chemoradiation with weekly nedaplatin in patients with squamous cell carcinoma of the uterine cervix

Gynecologic Oncology

Volumn 104, Issue 1, 2007, Pages 36-40

  Yoshinaga, Kohsuke ^a   Niikura, Hitoshi ^a   Ogawa, Yoshihiro ^a   Nemoto, Kenji ^b   Nagase, Satoru ^a   Takano, Tadao ^a   Ito, Kiyoshi ^a   Yaegashi, Nobuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

Cervical cancer; Chemoradiation; Concurrent; Nedaplatin; Pharmacokinetics

Indexed keywords

ANTIEMETIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; NEDAPLATIN; PLATINUM; SEROTONIN 3 ANTAGONIST;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE COMPARISON; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; LEUKOPENIA; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TELETHERAPY; TREATMENT DURATION; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PLATINUM; RADIOISOTOPE TELETHERAPY; UTERINE CERVICAL NEOPLASMS;

EID: 33846031620     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.06.034     Document Type: Article

References (27)

1. Shiratori O., Kanai H., Uchida N., Takeda Y., Totani T., and Sato K. Antitumor activity and toxicity of 254-S, a platinum complex, in rodents. In: Ishibashi J. (Ed). Recent advances in chemotherapy (1985), University of Tokyo Press, Tokyo 635-636
2. Hartmann J.T., and Lipp H.P. Toxicity of platinum compounds. Expert Opin. Pharmacother. 4 (2003) 889-901
3. Sasaki Y., Amano T., Morita M., Shinkai T., Eguchi K., Tamura T., et al. Phase I study and pharmacological analysis of cisdiammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Cancer Res. 51 (1991) 1472-1477
4. Koshiyama M., Kinezaki M., Uchida T., and Sumitomo M. Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin. Anticancer Res. 25 6C (2005) 4499-4502
5. Ota K., Oguma T., and Shimamura K. Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S. Anticancer Res. 14 (1994) 1383-1387
6. Weiss G.R., Green S., Hannigan E.V., Boutselis J.G., Surwit E.A., Wallace D.L., et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol. Oncol. 39 (1990) 332-336
7. McGuire III W.P., Arseneau J., Blessing J.A., DiSaia P.J., Hatch K.D., Given Jr. F.T., et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 7 (1989) 1462-1468
8. Kato T., Nishimura H., Yakushiji M., Noda K., Terashima Y., Takeuchi S., et al. Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer. Gan To Kagaku Ryoho 19 (1992) 695-701
9. Hirabayashi K., and Okada E. Combination chemotherapy with 254-S, ifosfamide, and peplomycin for advanced or recurrent cervical cancer. Cancer 71 (1993) 2769-2775
10. National Cancer Institute: NCI Clinical Announcement. Bethesda, MD: United States Department of Health and Human Services, Public Health Service, National Institutes of Health, February 1999.
11. Hasegawa Y., Takanashi S., Okudera K., Aoki M., Basaki K., Kondo H., et al. Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study. Jpn. J. Clin. Oncol. 34 (2004) 647-653
12. Kato H., Fukuchi M., Manda R., Nakajima M., Miyazaki T., Sohda M., et al. Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas. Anticancer Res. 23 (2003) 3493-3498
13. Nemoto K., Matsushita H., Ogawa Y., Takeda K., Takahashi C., Britton K.R., et al. Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. Am. J. Clin. Oncol. 26 (2003) 46-49
14. Ita M., Okafuji M., Fukuda K., Mitsuoka K., Hanakita T., and Hayatsu Y. Concurrent chemoradiotherapy with new platinum compound nedaplatin in oral cancer. Oral. Oncol. 39 (2003) 144-149
15. Yamanaka H., Motohiro T., Michiura T., Asai A., Mori T., and Hioki K. Nedaplatin and 5-FU combined with radiation in the treatment for esophageal cancer. Jpn. J. Thorac. Cardiovasc. Surg. 46 (1998) 943-948
16. Kawase S, Okuda T, Ikeda M, Ishihara S, Itoh Y, Yanagawa S, Ishigaki T, Intraarterial cisplatin/nedaplatin and intravenous 5-fluorouracil with concurrent radiation therapy for patients with high-risk uterine cervical cancer. Gynecol. Oncol in press.
17. Onishi Y., Nakamura T., Hatae M., Adachi S., and Ogasawara T. Phase I study of weekly and radiation therapy for advanced cervical cancer. Proc. ASCO 21 (2002) 111
18. National Cancer Institute-Common Toxicity Criteria Version 2.0, issued Jan. 30, 1998. Accessed at http://www.ctep.cancer.gov/reporting/ctc.html.
19. Therasse P., Arbuck S.G., Eisenhauer A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J. Nat. Cancer Inst. 92 (2000) 205-216
20. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J. Clin. Oncol. 14 (1996) 1957-1960
21. Gralla R.J., Osoba D., Kris M.G., Kirkbride P., Hesketh P.J., Chinnery L.W., et al. American Society of Clinical Oncology. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J. Clin. Oncol. 17 (1999) 2971-2994
22. Ogawa Y., Nemoto K., Kakuto Y., Ariga H., Matsushita H., Takeda K., et al. Results of radiation therapy for uterine cervical cancer using high dose rate remote after loading system. Tohoku J. Exp. Med. 199 (2003) 229-238
23. Matsumoto Y., Ishiko O., Nakagawa E., Sumi T., Hyun Y., Ando Y., et al. Pharmacokinetics and pharmacodynamics of serum platinum of gynecologic cancer patients treated with nedaplatin. Oncol. Rep. 8 (2001) 1269-1273
24. Ishibashi T., Yano Y., and Oguma T. Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis. Anticancer Res. 25 (2005) 1273-1281
25. Ishibashi T., Yano Y., and Oguma T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br. J. Clin. Pharmacol. 56 (2003) 205-213
26. Eifel P.J., Moughan J., Owen J., Katz A., Mahon I., and Hanks G.E. Patterns of radiotherapy practice for patients with squamous carcinoma of the uterine cervix: patterns of care study. Int. J. Radiat. Oncol. Biol. Phys. 43 (1999) 351-358
27. Toita T., Moromizato H., Ogawa K., Kakinohana Y., Maehama T., Kanazawa K., et al. Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer. Gynecol. Oncol. 96 (2005) 665-670